NeuroVive Pharmaceutical AB (publ) (STO:NVP), the mitochondrial medicine company, reports that the phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart attack known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results